

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

**APPLICATION NUMBER: 20-521**

---

**MICROBIOLOGY REVIEW(S)**

REVIEW FOR DIVISION OF PULMONARY DRUG PRODUCTS, HFD-570  
OFFICE OF NEW DRUG CHEMISTRY, MICROBIOLOGY STAFF, HFD-805  
MICROBIOLOGIST'S REVIEW NO. 2  
March 6, 1997

MICROBIOLOGY REVIEWER: Carol K. Vincent

A. 1. NDA No.: 20-521

DRUG PRODUCT-NAME: Infasurf Intratracheal Suspension  
(Calf Lung Surfactant Extract)

APPLICANT: Ony, Inc.  
Baird Research Park  
1576 Sweet Home Road  
Amherst, New York 14228

2. DOSAGE FORM AND ROUTE OF ADMINISTRATION:  
Sterile suspension for intratracheal administration.

3. METHOD(s) OF STERILIZATION:

4. PHARMACOLOGICAL CATEGORY AND/OR PRINCIPAL INDICATION:  
The drug product is intended for prevention of respiratory distress syndrome (RDS) in premature infants and treatment ("rescue") of newborn infants who develop RDS.

5. DRUG PRIORITY CLASSIFICATION: 1 S, Orphan drug designation, June 7, 1985

B. 1. DOCUMENT DATE: 11-06-96

2. DOCUMENT RECEIVED FOR REVIEW: 02-03-97

C. REMARKS: This amendment responds to the Division's Approvable letter dated July 25, 1996. Only items 17 and 18 are relevant for microbiology review. These respond to the two requests in MICROBIOLOGIST'S REVIEW NO. 1 DATED JULY 10, 1996 recommending approval for this application.

D. CONCLUSION and RECOMMENDATION: The information provided is acceptable and satisfies all previous requests for microbiology information. We recommend approval for sterility assurance for this application.

See "E. REVIEW NOTES:" below.

cc:  
Orig. NDA 20-521  
HFD-160/Consult/CKVincent [HFD-805]  
HFD-155/Himmel/Pina/Nashed [redacted]  
Drafted by: CKVincent/03-07-97  
R/D Init by: PHCooney/03-07-97

*Discussion for PHCooney 3/7/97*

*ISI*

Carol K. Vincent  
Review Microbiologist [HFD-805]

*3-7-97*

REVIEW FOR DIVISION OF PULMONARY DRUG PRODUCTS, HFD-570  
 OFFICE OF NEW DRUG CHEMISTRY, MICROBIOLOGY STAFF, HFD-805  
 Addendum No. 1 to MICROBIOLOGIST'S REVIEW NO. 1  
 July 12, 1996

MICROBIOLOGY REVIEWER: Carol K. Vincent

A. 1. NDA No.: 20-521

DRUG PRODUCT NAME: Infasurf Intratracheal Suspension  
 (Calf Lung Surfactant Extract)

APPLICANT: Ony, Inc.  
 Baird Research Park  
 1576 Sweet Home Road  
 Amherst, New York 14228

B. 1. AMENDMENT: (by fax) 07-11-96  
 2. DOCUMENT (fax) RECEIVED FOR REVIEW: 07-11-96

C. REMARKS: MICROBIOLOGIST'S REVIEW NO. 1 FOR NDA 20-521 DATED 07-10-96 contained remarks describing a telephone conversation with Dr. Egan to "clarify the specification for "sterility" for the final product release." Dr. Egan committed to provide a modified final release specification for the product based on this discussion.

The information in the material dated and received 07-11-96 provides that modified release specification.

D. CONCLUSION: We recommend approval for sterility assurance for Infasurf based on the sterilization process validation information submitted by the applicant. The information in this amendment does not alter the previous recommendation for approval.

See "E. REVIEW NOTES:" and "DRAFT OF LETTER TO APPLICANT", below.

cc:

Orig. NDA 20-521

HFD-160/Consult/CKVincent (HFD-805)

HFD-155/Himmel/Pina/Nashed/Kuzimak

Drafted by: CKVincent/07-12-96

R/D Init by: PHCooney/07-12-96

/S/

Carol K. Vincent  
 Review Microbiologist (HFD-805)

JKC 7/12/96

7-12-96

REVIEW FOR DIVISION OF PULMONARY DRUG PRODUCTS, HFD-570  
 OFFICE OF NEW DRUG CHEMISTRY, MICROBIOLOGY STAFF, HFD-805  
 MICROBIOLOGIST'S REVIEW NO. 1  
 July 10, 1996

MICROBIOLOGY REVIEWER: Carol K. Vincent

A. 1. NDA No.: 20-521

DRUG PRODUCT NAME: Infasurf Intratracheal Suspension  
 (Calf Lung Surfactant Extract)

APPLICANT: Ony, Inc.  
 Baird Research Park  
 1576 Sweet Home Road  
 Amherst, New York 14228

2. DOSAGE FORM AND ROUTE OF ADMINISTRATION:  
 Sterile suspension for intratracheal administration.

3. METHOD(s) OF STERILIZATION:

4. PHARMACOLOGICAL CATEGORY AND/OR PRINCIPAL INDICATION:  
 The drug product is intended for prevention of respiratory distress syndrome (RDS) in premature infants and treatment ("rescue") of newborn infants who develop RDS.

5. DRUG PRIORITY CLASSIFICATION: 1 S, Orphan drug designation, June 7, 1985


B. 1. DOCUMENT DATE: 03-13-95  
 2. RESUBMITTED: 07-27-95  
 3. FILING DATE: 07-31-95  
 4. DOCUMENT RECEIVED FOR REVIEW: 08-10-95  
 5. AMENDMENT: 02-08-96  
 6. DOCUMENT RECEIVED FOR REVIEW: 02-20-96

C. REMARKS: The manufacturer, Ony, Inc., has been granted the "Small Business Exception" and the deferred, reduced User Fee because it has "no prescription drug product introduced or delivered for introduction into interstate commerce" [p 2, A. Pedersen letter, Vol 21].

1. I telephoned Dr. Egan, Ony, Inc., on July 3, 1996 to clarify the specification for "sterility" for the final product release. He faxed the company's SOP 8.2.2 dated 09-15-95

Since section 3.4.7.1.5 Methods and controls to monitor

clearly indicates that



Dr. Egan committed to provide a modified final release specification for the product based on this discussion.

We do note that the Chemistry review dated 02-15-96 includes a table (p 25) listing Finished drug product specifications and tests which cites an August 10, 1995 submission (not provided for microbiology review) listing the USP Chapter <71> method for the parameter, sterility.

We also request that the applicant inform the Division if the geographic source for the live animals or slaughter changes. A brief amendment to the pending application or inclusion of this material in the annual report for an approved application will be satisfactory.

D. CONCLUSION: We recommend approval for sterility assurance for Infasurf based on the sterilization process validation information submitted by the applicant provided that the applicant commits to:

See "E. REVIEW NOTES:" and "DRAFT OF LETTER TO APPLICANT", below.

cc:  
Orig. NDA 20-521  
HFD-160/Consult/CKVincent [HFD-805]  
HFD-155/Himmel/Pina/Nashed/Kuzimak  
Drafted by: CKVincent/01-17-96/05-30-96  
Revised by: CKVincent/06-13-96/07-02-96/07-10-96  
R/D Init by: PHCooney/07-03-96

ISI 7-10-96

Carol K. Vincent  
Review Microbiologist [HFD-805]

ISI 7/10/96